CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC), Artos Ltd. Enter Agreement to Expand Offering of Cannabis Products for Israeli Market

Flora (NASDAQ: FLGC), a leading all-outdoor cultivator and manufacturer of global cannabis products and brands, has announced its entry into an agreement with Artos Ltd. to sell approximately 3,600 kg of dried high-THC cannabis flower to Israel from its Cosechemos cultivation facility. Through the agreement, Flora seeks to establish a partnership with the Artos team to expand their offering of cannabis products for the Israeli market to also include oils and, when regulations permit, finished THC and CBD consumer products. The export of the high-THC product is pending the dried-flower checklist from the Colombian government from the 2021 cannabis law update. “As Cosechemos continues to reach full-scale commercial production, our team remains focused on increasing our presence in international cannabis markets through distribution agreements that will serve as a gateway into the markets,” said Luis Merchan, CEO of Flora Growth. “With Artos’ extensive distribution network, this agreement will ensure that safe, high-quality cannabis products are provided to the Israeli cannabis market and offer a valuable source of health and wellness products to the country.”

To view the full press release, visit https://cnw.fm/eBWvJ

About Flora Growth Corp.

Flora is building a design-led collective of plant-based wellness and lifestyle brands delivering the most compelling customer experiences in the world, one community at a time. As the operator of one of the largest outdoor cannabis cultivation facilities, Flora leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — New Congressional Bill Plans to Raise THC Limit for Hemp

Earlier this week, Rep. Chellie Pingree filed a measure which will make some crucial reforms to the hemp industry, including increasing the legal threshold for THC in hemp products to 1% from 0.3% on a dry weight basis. The measure, dubbed the Hemp Advancement Act, would also address an issue associated with levels of THC for in-process hemp.

Many businesses had raised concerns about the THC limit stipulated under the existing federal statute previously, as the process of extracting hemp could temporarily increase the content of THC in a plant in a way that made them liable for enforcement action.

Under this Congressional bill, in-process hemp wouldn’t be subject to any THC thresholds as long as the final product didn’t exceed 1%. This new 1% limit would include delta-9 THC, which is the commonly known psychoactive component in hemp, as well as variants like delta-10 and delta-8, which aren’t as popular but are still available in markets where marijuana hasn’t been legalized.

The measure would also eliminate a requirement stipulated under the 2018 Farm Bill that the plants can only be tested at labs registered by the DEA. In a phone interview, Pingree stated that there weren’t enough testing facilities for hemp across the country, noting that there wasn’t even one lab in Maine while there were only 2 covering New England.

She explained that laboratories which weren’t certified by the DEA were also capable of testing the crop, adding that removing this requirement would eliminate one obstacle farmers faced, as that hemp was an agricultural crop that only needed to be evaluated for appropriate reasons.

The measure would also eliminate a provision in the 2018 Farm Bill which prevents individuals who’ve been charged with drug-related felony convictions in the past decade from participating in the hemp industry. Advocates have in the past argued that this provision perpetuated racial disparities by excluding individuals from communities which had been disproportionately affected by marijuana prohibition. The congresswoman explained that the ban treated hemp like a controlled substance which wasn’t the case, as hemp was an agricultural crop.

She added that prohibiting individuals using this rule was damaging to people who’d like to take part in the industry, as well as the industry as a whole, given the labor shortage in this market.

The measure is being backed by more than ten major cannabis and hemp groups, including the Hemp Industries Association, Americans for Safe Access and the U.S. Hemp Roundtable.

If these proposed changes are eventually enacted into law, we are likely to see firms like Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) growing at a faster rate due to the easing of some of the rules which were making operations a tad more complex.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Veteran Cannabis Lobbyist Unveils New Political Group

Last week a veteran marijuana lobbyist launched a new political action commission (“PAC”) that will push for reforms designed to end federal marijuana prohibition. The Better Organizing to Win Legalization (“BOWL”) PAC will also work with other organizations to support politicians and elected officials who are advancing reforms for marijuana legalization.

Justin Strekal launched BOWL PAC with the aim of encouraging organizations and advocacy groups that are not actively involved to be more proactive in backing efforts for legalization.

Strekal said he intends to reach out  to organizations and groups that say they are supporting cannabis legalization but “are not actively engaged.” He aims to bridge that gap by educating the organizations and groups about how to become more involved in demanding reforms.

Strekal is a veteran lobbyist with more than five years as the political director of NORML.

BOWL PAC considers the 2022 elections to be the first challenge it will face. The group is working on a targeted timeline strategically designed to engage with voters. It hopes to convince voters as they head to the polls that through their choice, cannabis “legalization is on the battlefield.” However, details of targeted campaign contributions or financing options have not been disclosed.

The group has launched an online petition demanding President Joseph Biden to fulfill his campaign promise on cannabis reforms, including ending marijuana’s federal criminalization that has seen users face jail time. Despite Biden finishing his first year in office, he has yet to fulfill his campaign pledges. He promised that the federal prohibition of cannabis would be lifted, but laws that put people in prison over minor marijuana offenses continue to exist and be enforced.

The Biden Administration’s failure to follow through with its campaign statements has seen individual states implement marijuana reforms. Toi Hutchinson, CEO of the Marijuana Policy Project, said that the current situation has led to social inequity where individuals in one state can compete for licenses to produce and sell cannabis while individuals in another state are facing criminal prosecutions. Morgan Fox, NORML’s newly appointed political director said the inactions of the Biden administration are a betrayal to the people who voted for the president.

With his new PAC, Strekal aims to offer resources that were underutilized at NORML in supporting efforts calling for social reforms while defeating the detractors calling for marijuana’s prohibition.

The ending of federal cannabis prohibition is likely to usher in a period of rapid growth for sector players such as American Cannabis Partners due to the wider market that will be available to them around the country.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Data from UK Registry Reveals Medical Marijuana Improves Patients’ Quality of Life

A study conducted by the UK Medical Cannabis Registry reveals the association between prescribed medical marijuana and an improvement in the quality of life of a patient. The UK Medical Cannabis Registry is a first-of-its-kind database known to contain details of the largest group of patients that have been prescribed medical marijuana.

The registry was set up by Sapphire Medical, a medical cannabis clinic providing patients with an expert assessment of their health conditions and considerations for using medicinal cannabis for treatment. The data in the registry is anonymous and is available upon request to the medical community.

The study findings were published in the registry by “Cannabis and Cannabinoid Research,” an internationally peer-reviewed journal. The study analyzed data collected from 312 patients who were diagnosed with anxiety, chronic and neuropathic pain, fibromyalgia and needed palliative care over a period of six months. The demographic distribution revealed that the mean age was 45 with male participants accounting for 55% while 45% were female. Out of the total participants, 36% had used marijuana daily before the treatment. Data was collected while building up on research from Canada and New Zealand.

Generalized anxiety disorder was a common diagnosis across the patients. The anxiety score on average was consistent, which according to the results would reduce to below clinically relevant levels during a follow-up.

Medical cannabis was also found to have an effect on patients with chronic illnesses. It was found that one in four patients reported having symptoms of anxiety within the previous two weeks and then found relief. In terms of adverse events, 94 patients (30.1%) reported experiencing nausea frequently (3.8%) with other mild symptoms, including dizziness, dry mouth and sleepiness.

Sapphire Medical also mentioned that patients reported an improvement in the quality of sleep. However, due to the design and the nature of the study, these reports could not be linked to the use of prescribed medical marijuana.

This study followed a previous study that was published last year. Similarly, that study used data from the medical cannabis registry and noted significant improvements in pain, anxiety, sleep and quality of life after scoring patients one to three months after receiving treatment.

Since 2018, doctors in the United Kingdom are allowed by law to prescribe medical cannabis to patients under certain circumstances. According to Hemp Gazette, another piece of legislation is in motion that aims to expand the ability of general health practitioners to prescribe unaccredited cannabis medical products.

This data provides yet more proof that the cannabis products manufactured by licensed entities such as Cannabis Strategic Ventures Inc. (OTC: NUGS) from around the world can be pivotal in benefiting patients who would have otherwise failed to derive similar benefits from conventional medications.

NOTE TO INVESTORS: The latest news and updates relating to Cannabis Strategic Ventures Inc. (OTC: NUGS) are available in the company’s newsroom at http://cnw.fm/NUGS

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Report Finds Marijuana Has Contributed $43+ Billion to Canada’s GDP

A recent report by Deloitte Canada states that marijuana has contributed more than $43 billion to the country’s gross domestic product (“GDP”). Since recreational marijuana was legalized in 2018, it has also contributed more than $13 billion to Ontario’s GDP.

The report, which was compiled with help from the Ontario Cannabis Store, stated that for every $1 in capital expenditures or revenue, the marijuana industry added roughly $1.02 and $1.09 to Ontario’s and Canada’s gross domestic product from legal purchases. The Ontario Cannabis Store is a provincial distributor of cannabis.

The report also provides insight into how the marijuana industry in Canada has impacted the nation’s finances over the past few years. For example, it states that in three years, the country’s marijuana sector has emerged as a burgeoning new source of economic growth, supporting and creating thousands of employment opportunities in various communities. Thus far, the cannabis industry has created more than 150,000 jobs and sustains roughly four jobs in Ontario and Canada each for every million dollars in capital expenditure or revenue.

The report also noted that it expected the sector to make an increasingly positive and strong impact on provincial and national economies as it matured and grew. Report estimates show that the cannabis industry has generated an estimated $3 billion and $15 billion in tax revenues for Ontario and Canada as a whole, respectively. Consumer purchases alone have generated $2.9 billion in excise and sales taxes.

The estimates also show that at the Ontario level, marijuana producers and retailers were responsible for $1.2 billion in indirect taxes, $141 million in direct taxes and $674 million in other taxes, while consumer purchases brought in $1 billion in excise and sales taxes.

With regard to diversity within the industry, the report found that not much had changed since marijuana was legalized in October 2018. Before legalization, almost all federally licensed marijuana producers were managed by Caucasian men. It cited a study conducted by the University of Toronto and the Center on Drug Policy Evaluation which found that racialized women and men were considerably underrepresented among marijuana company directors and executives.

This study gathered responses from 700 directors and executives from more than 200 firms. It found that of the total number, 72% were Caucasian men, 14% were racialized men, 12% were Caucasian women and 2% were racialized women. The racialized portion encompasses South Asian, East Asian, Indigenous, Arab, Hispanic and Black individuals.

The stats on the type of contribution the cannabis sector has made to the GDP of Canada is an indirect bill of health for entities such as Flora Growth Corp. (NASDAQ: FLGC), which operate within the legal cannabis industry in Canada and beyond because the health of these companies translates into greater tax revenues and salaries for employees as well as other multiplier effects.

NOTE TO INVESTORS: The latest news and updates relating to Flora Growth Corp. (NASDAQ: FLGC) are available in the company’s newsroom at https://cnw.fm/FLGC

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) in Unique Position to Offer Full Slate of Rare Cannabinoid Manufacturing Technologies

InMed Pharmaceuticals (NASDAQ: INM) understands the immense potential of rare cannabinoids and sees them as having applications as wide as cannabidiol (“CBD”) and tetrahydrocannabinol (“THC”), variants of cannabinoids that make up most of the content in cannabis plants. Studies suggest that rare cannabinoids could offer more potent medical benefits than CBD and without the psychoactive attribute of THC, representing a huge market. “However, the industry wide problem has always been to obtain the production scales necessary for cost-effective commercialization of such compounds, while also ensuring the purity and consistency that can be difficult at even low volumes. The answer is to develop and apply successful large-scale bio-synthesis capabilities, technologies that are complex and not readily available for these rare compounds,” explains a recent article. In October last year, InMed acquired BayMedica, adding its synthetic biology and chemical synthesis capabilities and expertise to InMed’s bacterial biosynthesis and enzymatic biotransformation capabilities. The acquisition provides InMed with complete rare cannabinoid manufacturing flexibility to select the most appropriate, cost-effective method based on the target cannabinoid and applicable quality specifications for the desired industry. “I think we are the only company out there that can offer a full slate of these different manufacturing technologies,” stated InMed CEO Eric A. Adams.

To view the full article, visit https://cnw.fm/VxnL5

About InMed Pharmaceuticals Inc.

InMed Pharmaceuticals is a global leader in the development, manufacturing and commercialization of rare cannabinoids. Together with its subsidiary, BayMedica, the company has unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is also a clinical-stage company developing a pipeline of rare cannabinoid therapeutics and dedicated to delivering new treatment alternatives to patients that may benefit from cannabinoid-based pharmaceutical drugs. For more information, visit www.InMedPharma.com and www.BayMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to INM are available in the company’s newsroom at https://cnw.fm/INM

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Flora Growth Corp. (NASDAQ: FLGC) Furthering Global Foothold as Leader in Plant-Based Wellness, Lifestyle Brands

Flora Growth Corp. (NASDAQ: FLGC) is expanding its cannabis-derived brand presence in Latin American countries. Its Mind Naturals skincare brand, built with premium CBD and other high-quality ingredients, will be distributing a portfolio of 12 products through its agreement with Walmart’s online marketplace and Coppel e-commerce outlets. Walmart and Coppel are leading retail chains in Mexico and Central America. A recent article quotes Flora Growth CEO Luis Merchan as saying, “This agreement represents our first foray into the Mexican market and furthers our global foothold as a leader in plant-based wellness and lifestyle brands… As the cannabis market continues its rapid expansion across the globe and into various sectors, we are poised to meet the needs of the market at every touch point.” Merchan separately shared via the Bell2Bell Podcast that 2021 was a foundational year for the company as it established its infrastructure to capitalize on its first revenues and set the stage for continued growth. “In 2022, we’re going to see the export of dried flower commerce. We’re going to see the export of derivatives into countries such as Australia, South Africa and some portions of Europe, and that, of course, will be complemented by organic growth in our portfolio products.”

To view the full article, visit https://cnw.fm/6rzKI

About Flora Growth Corp.

Flora is a cannabis company that leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions of cosmetics, hemp textiles, and food and beverage. As the operator of one of the largest outdoor cultivation facilities, Flora strives to market a higher-quality premium product at below-market prices. By prioritizing natural ingredients and value-chain sustainability across its portfolio, Flora creates premium products that help consumers restore and thrive. Visit www.FloraGrowth.ca or follow @floragrowthcorp on social for more information.

NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://cnw.fm/FLGC

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.

420 with CNW — Cosmetics Sector Now Eying CBG as an Ingredient

We’ve seen the CBD market grow significantly these last few months in different parts of the globe, with projections showing that by 2028, the market could be valued at $13 billion. CBD has various benefits, which include relieving anxiety and providing pain relief along with anti-acne and anti-seizure properties. Some studies have also found that CBD may help prevent growth of cancer cells. However, more research is needed to support these claims.

CBD isn’t the only compound various markets are interested in either, as the wellness and cosmetic markets have begun to take an interest in CBG (cannabigerol), which is said to possess anti-inflammatory, antibacterial and soothing properties.

Like CBD, CBG is one of the many compounds found in the cannabis plant, which contains more than 100 cannabinoids. Other cannabinoid compounds include cannabichromene, cannabidiorcol, cannabichromenevarin, tetrahydrocannabinolic acid, cannabinol, cannabidiolic acid synthase and cannabichromanon.

Unlike CBD and THC, which are the primary compounds in the cannabis plant, CBG is less known. Despite being less recognized, manufacturers and researchers have begun exploring CBG’s potential in an effort to introduce it to the realm of beauty and wellness.

CBG is, in some way, the basis of its counterparts as it transforms into other cannabinoids, including THC and CBD, during the cannabis plant’s growth. This may explain why it is found in relatively low concentrations and small quantities.

In addition to this, CBG is nonpsychotropic, like CBD, which means that it does not induce a high. This is unlike THC, which causes individuals to get high when they ingest or consume cannabis.

CBD is currently used in many products, including creams, serums, oils, scrubs, cleansers and deodorants. We may, in the near future, see the same lines of products with CBG. Some companies are already looking closer at the properties of CBG various studies and have found their antioxidant, antibacterial, soothing and anti-inflammatory properties.

CBG oils, which many believe can help combat fatigue and stress, are already available in various specialist stores. These oils are also said to relieve anxiety, help manage pain, alleviate inflammation, relieve nausea and relieve a number of skin conditions, including acne.

The cosmetics industry plans to use this compound to create an even wider range of products for the skin. For example, Purple Store, the France-based network of specialist CBD boutiques, recently announced that it would begin the development of cannabigerol-based products, which could range from cosmetics to wellness products. This announcement came after CBG was included in the EU’s database of cosmetics ingredients last year.

As more studies unearth the benefits of other cannabinoids, we will undoubtedly see sector players such as Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) developing new product ranges featuring those novel cannabinoids.

NOTE TO INVESTORS: The latest news and updates relating to Red White & Bloom Brands Inc. (CSE: RWB) (OTCQX: RWBYF) are available in the company’s newsroom at https://cnw.fm/RWBYF

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

420 with CNW — Proposed California Law Could Push Back on Marijuana Legalization

A California assembly member is proposing a new law that will recriminalize the growing of marijuana. The bill seeks to treat unlicensed cannabis cultivation of more than six plants as a felony. This is pushing back on the state’s Adult Use of Marijuana Act that was passed in 2016. The legislation removed all weed-related felonies and stipulated that offenders could only go to prison if they were caught selling to minors.

The Assembly Bill 1725 by Rep. Thurston Smith (R-Apple Valley) is seeking to undo that act by increasing the penalties for unlicensed marijuana cultivation from a misdemeanor to a felony offense. Misdemeanors tend to receive a $1,000 fine with up to one year in jail with first-time violators receiving a fine. As a felony, this would mean violators would receive at least 16 months to three years in jail. For the bill to pass, it will require a two-thirds majority in a Democrat-dominated legislature.

The assembly member said in a news release that the bill would fight off illicit farmers who have been “operating with impunity.” He said that this was as a result of Sacramento lawmakers being “soft on crime” and thus causing an increase in unlicensed grows.

The bill has received criticism with an East Bay Express article arguing that despite the war on drugs ending in 2016 and realizing that criminal enforcement does not reduce the market share of illicit grows, some legislators are pretending not to understand. The publication goes on to note that San Bernardino has put a ban in place that prohibits any commercial activity on marijuana. As a result, unlicensed grows have popped up for years because they generate money, and the article states that “it’s worth the risk of criminal prosecution.”

The assembly member’s district contains a track of desert land whose climatic and soil conditions provide an ideal state for the cultivation of cannabis. Smith has been in favor of police raids including one that led to 15 arrests. One report for the San Bernardino County Board revealed that the conditions in the desert resulted in 1,080 illicit farms, out of which 300 were busted in 2021. In August, Shannon Dicus, a county sheriff, informed the board that the pot farms posed a threat to the quality of life in the area, citing that they have created environmental harms through the misuse of insecticides.

East Bay Express argues that government officials should allow cannabis farms to operate legally because criminal enforcement does not reduce the number of illegal cultivation sites. A Forbes report states the assembly member’s efforts “represent a growing discontent” with the way implementation of laws around marijuana legalization has played out. The problem is that the laws can only be fixed through reform policies at the state and federal level, a move that would address many of the regulatory headaches which the industry, including companies such as American Cannabis Partners, currently faces.

NOTE TO INVESTORS: The latest news and updates relating to American Cannabis Partners are available in the company’s newsroom at https://cnw.fm/ACP

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) to Be Evaluated for Potential Treatment Options for Multiple Conditions

Lexaria Bioscience Corp. (NASDAQ: LEXX) CEO Chris Bunka noted that Lexaria would continue to see significant milestones in utilizing its patented DehydraTECH drug delivery technology in 2022. “Calendar 2022 will continue to see significant milestones utilizing DehydraTECH-CBD for investigation of heart disease and hypertension; and separately, for oral nicotine delivery as an alternative to smoking… We are delighted to announce that DehydraTECH as an enhanced drug delivery platform will also be evaluated for characteristics and potential treatment options for hormone replacement, dementia, rheumatoid disease and diabetes,” a recent article quotes Bunka as saying. Lexaria received independent review board approval, marking a significant milestone for its 2022 R&D program. “The approval sets the stage for the HYPER-H21-4 study that could define Lexaria’s future. The HOR-A22-1 study, scheduled to start in April 2022, will evaluate DehydraTECH’s ability to enhance the delivery characteristics of estrogen. DEM-A22-1, expected to begin in July 2022, will evaluate DehydraTECH-CBD with or without nicotine for the potential treatment of dementia. Lexaria also plans to execute on the RHEUM-A22-1 and DIAB-A22-1 studies, scheduled for October and November, respectively…”

To view the full article, visit https://cnw.fm/HGULY

About Lexaria Bioscience Corp.

Lexaria’s patented drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (“APIs”) enter the bloodstream by promoting more effective oral delivery. Since 2016, DehydraTECH has repeatedly demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce time of onset from one to two hours to minutes, and mask unwanted tastes. The technology is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (“NSAIDs”), PDE5 inhibitors and more. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood brain barrier. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 23 patents granted and over 50 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://cnw.fm/LEXX

About CannabisNewsWire

CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive SMS text alerts from CannabisNewsWire, text “CANNABIS” to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CannabisNewsWire.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have questions or are you interested in working with CNW? Ask our Editor

CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsWire is part of the InvestorBrandNetwork.